Drug Profile

Elegrobart - Viridian Therapeutics

Alternative Names: VRDN 003; ZL-1109

Latest Information Update: 03 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Viridian Therapeutics
Developer Viridian Therapeutics; ZAI Lab
Class Eye disorder therapies; Monoclonal antibodies
Mechanism of Action IGF type 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Graves ophthalmopathy

Most Recent Events

01 Jul 2026 Elegrobart license to Zai Lab in China, Hong Kong, Macau, and Taiwan
01 Jul 2026 Zenas Biopharma in-licenses elegrobart from Viridian Therapeutics for China, Hong Kong, Macau, Taiwan
28 May 2026 Viridian Therapeutics completes a phase III trial for Graves ophthalmopathy in the US (SC) (NCT07155668)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com